icad inc. (ICAD): Price and Financial Metrics

icad inc. (ICAD)

Today's Latest Price: $9.78 USD

0.44 (4.71%)

Updated Nov 27 1:00pm

Add ICAD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ICAD Stock Summary

  • ICAD's price/sales ratio is 7.85; that's higher than the P/S ratio of 81.8% of US stocks.
  • With a year-over-year growth in debt of -51.63%, Icad Inc's debt growth rate surpasses only 5.87% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Icad Inc is reporting a growth rate of 46.88%; that's higher than 81.03% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Icad Inc, a group of peers worth examining would be MBII, APDN, NBRV, FLDM, and STXS.
  • Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.

ICAD Stock Price Chart Interactive Chart >

Price chart for ICAD

ICAD Price/Volume Stats

Current price $9.78 52-week high $15.31
Prev. close $9.34 52-week low $5.91
Day low $9.30 Volume 168,500
Day high $10.02 Avg. volume 272,781
50-day MA $9.59 Dividend yield N/A
200-day MA $10.22 Market Cap 224.87M

icad inc. (ICAD) Company Bio

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.

ICAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream

Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about Icad Inc that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

iCAD, Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by iCAD, Inc. in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 5, 2020

iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2020 Results - Earnings Call Transcript

iCAD, Inc. (ICAD) Q2 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Michael Klein - Chairman and Chief Executive Officer Scott Areglado - Chief Financial Officer Stacey Stevens - President Conference Call Participants Dave Turkaly - JMP Securities Per Ostlund -...

SA Transcripts on Seeking Alpha | August 5, 2020

Is iCAD (NASDAQ:ICAD) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | July 24, 2020

iCAD Appoints Jeffrey Sirek as Senior Vice President and General Manager of Xoft

NASHUA, N.H., July 20, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced.

Yahoo | July 20, 2020

ProFound AI™ Risk Receives CE Mark in Europe

First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman iCAD unveils new.

Yahoo | July 15, 2020

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo -1.21%
3-mo -3.26%
6-mo -22.69%
1-year 30.23%
3-year 171.67%
5-year 139.71%
YTD 25.87%
2019 110.00%
2018 7.56%
2017 6.50%
2016 -37.52%
2015 -43.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8485 seconds.